CD274 and non-small cell lung carcinoma: For patients with non-oncogene-addicted metastatic NSCLC (LUSC or non-LUSC), low PD-L1 expression, and performance status 2, cytotoxic chemotherapy—gemcitabine (GEM) or docetaxel (DOC)—is still a mainstay [7,8].